Recent Finacing
Recent Raise
Aer Therapeutics develops inhaled small-molecule mucolytics targeting airway mucus biology, advancing lead candidate AER‑01 for liquefying mucus plugs in COPD and exploring asthma, bronchiectasis, and cystic fibrosis.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Aer Therapeutics.
